Search results
Showing 256 to 270 of 370 results for hypertension
NICE has developed a medtech innovation briefing (MIB) on InterDry for intertrigo .
This quality standard covers treating and managing psychosis and schizophrenia in adults (aged 18 and over) in primary, secondary and community care. It also includes support for the families and carers of people with psychosis or schizophrenia. It describes high-quality care in priority areas for improvement.
View quality statements for QS80Show all sections
Sections for QS80
- Quality statements
- Quality statement 1: Referral to early intervention in psychosis services
- Quality statement 2: Cognitive behavioural therapy
- Quality statement 3: Family intervention
- Quality statement 4: Treatment with clozapine
- Quality statement 5: Supported employment programmes
- Quality statement 6: Assessing physical health
- Quality statement 7: Promoting healthy eating, physical activity and smoking cessation
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (TA881)
Evidence-based recommendations on ripretinib (Qinlock) for treating gastrointestinal stromal tumour in adults after 3 or more treatments.
Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)
Evidence-based recommendations on lenvatinib (Lenvima) for untreated advanced hepatocellular carcinoma in adults.
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.
Evidence-based recommendations on durvalumab (Imfinzi) with tremelimumab (Imjudo) for untreated advanced or unresectable hepatocellular carcinoma in adults.
This guideline covers when to offer and discuss caesarean birth, procedural aspects of the operation, and care after caesarean birth. It aims to improve the consistency and quality of care for women and pregnant people who are thinking about having a caesarean birth or have had a caesarean birth in the past and are now pregnant again.
Evidence-based recommendations on abiraterone (Zytiga) for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults.
Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)
This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.
Summary of the evidence on topical timolol for treating infantile haemangioma (strawberry marks) to inform local NHS planning and decision-making
This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.
Tocilizumab for the treatment of rheumatoid arthritis (TA247)
Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis in adults.
This quality standard covers preventing, detecting and managing acute kidney injury in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS76Show all sections
Sections for QS76
- Quality statements
- Quality statement 1: Raising awareness in people at risk
- Quality statement 2: Identifying acute kidney injury in people admitted to hospital
- Quality statement 3: Response to acute kidney injury warning stage 2 test result
- Quality statement 4: Response to acute kidney injury warning stage 3 test result
- Quality statement 5: Referral for renal replacement therapy
- Quality statement 6: Clinical review after hospital discharge
- Update information
This guideline covers diagnosing and managing rheumatoid arthritis. It aims to improve quality of life by ensuring that people with rheumatoid arthritis have the right treatment to slow the progression of their condition and control their symptoms. People should also have rapid access to specialist care if their condition suddenly worsens.
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)
Evidence-based recommendations on ibrutinib (Imbruvica) with venetoclax (Venclyxto) for untreated chronic lymphocytic leukaemia in adults.